An official website of the United States Government 
Here's how you know

Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( lock ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

BAMC offers new prostate cancer therapy for patients

Oct. 26, 2022 | By Lori Newman
You have accessed part of a historical collection on defense.gov. Some of the information contained within may be outdated and links may not function. Please contact the DOD Webmaster with any questions.
The Brooke Army Medical Center Department of Nuclear Medicine is now offering a newly approved treatment for patients who have prostate cancer.

Other than skin cancer, prostate cancer is the most common cancer in American men. The American Cancer Society estimates that 268,490 men in the United States will be diagnosed with prostate cancer this year.

On March 23, 2022, the Food and Drug Administration approved the use of lutetium Lu 177 vipivotide tetraxetan for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy.

Full Story